Abstract:BackgroundEssential medicines are those drugs that satisfy the priority health care needs of the population and help with functioning healthcare systems. Although many countries have formulated an essential medicine list, almost half of the global population still lack regular access to essential medicines. Research about the initiation of National Essential Medicines Policy in Chinese secondary and tertiary hospitals is inadequate, and the long-term effect on access after the reform is still unknown. This study's objective was to investigate the access to essential medicines in mainland China's secondary and tertiary hospitals.MethodsData on the access to 30 essential medicines from China's National Essential Medicine List were obtained from China Medicine Economic Information database covering 396 secondary hospitals and 763 tertiary hospitals. We improved the standard methodology developed by the World Health Organization and the Health Action International to measure the availability, median price ratio (MPR) and the incidence of catastrophic drug expenditure (CDE).ResultsFive essential medicines had >50% availability and the nationwide availability kept steady; availability of drugs in eastern regions of China was significantly higher than the central and western regions. The median MPR of 30 drugs nationwide kept steady approximately 5; MPR of drugs in the eastern regions was significantly higher than the central and western regions and the ratio of MPR of innovator brands to generics increased from 3.66 to 6.32 during the study period. The incidence of CDE caused by essential medicines decreased from 2011 to 2014; brand name medicines were more likely to cause CDE than generics and rural patients have a greater tendency to fall into CDE.ConclusionsAfter the implementation of National Essential Medicines Policy, the MPR of essential medicines was well controlled and became more affordable in the context of steady availability. This has highlighted the problems associated with region disparity and inequity between rural and urban areas in the delivery of essential medicines and sustainable mechanisms are needed to deepen the National Essential Medicines Policy in mainland China.

Application of Pharmacoeconomics in the Management of National Essential Drug List

Evidence-based Research on the Selection Method System for China's Essential Medicine List

Health Technology Assessment and Its Use in Drug Policies in China

International Experience of Pharmacoeconomic Evaluation in Health Decision-making

Specific Role of Pharmacoeconomics in the Medical Reform Program Implementation

An Analysis of China's National Essential Medicines Policy

Conducting Pharmacoeconomics Studies to Provide Service for the Sustainable Development of Medical Insurance System

Consideration and Discussion of the Establishment and Improvement of Essential Medicine Financing Mechanism

The Application of Pharmacoeconomics in Clinical Medicine Decision Making

Bibliometric Analysis of Foreign Pharmacoeconomic Literatures

Quantity of Essential Drugs Supplement in China: Influential Factors, Reasonability and Control Methods

Assessment of the quality of pharmacoeconomic evaluation literature in China

Development and Practice of Pharmacoeconomics in Aisa-Pacific Region

A Survey of Availability, Price and Affordability of Essential Medicines from 2011 to 2016 in Chinese Secondary and Tertiary Hospitals

Comparative Study on the Policies of Drug Price and Expenditure Control in China and Other Countries

International Experience of Utilizing Pharmacoeconomic Evidences and the Application in China

[Expert consensus on pharmacoeconomic evaluations alongside clinical trials (2024 edition)]

Essential medicine policy in China: pros and cons.

Zero mark-up policy of essential medicines system in China:Problems and recommendations

A Critical Review of Chinese Pharmacoeconomics Studies in the Last Five Years.

Thinking on Linkage of Essential Drug List with Medical Insurance Directory and Reimbursement List of New Rural Co-operative Medical System